In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Licht 1:16 •    The interview 3:17     •    Can you tell us about your journey into hematology-oncology and how you ended up where you are today?  3:58 •    How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05 •    What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52 •    Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders?  18:39 •    What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20 •    How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23 •    Tell me about the process of achieving NCI designation and what it means for your institution. 36:25 •    How have you had to navigate state health care legislation and policies challenging reproductive health care?  42:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13 •    How to contact Licht 46:56 •    Thanks for listening 48:16 Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center. 

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email [email protected].  Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme.